Embracing Bayesian Methods in Clinical Trials

This Perspective discusses the importance of the US Food and Drug Administration’s draft guidance on the use of bayesian methods in clinical trials because it underscores its commitment to modernizing clinical research.

Corresponding Author: J. Jack Lee, PhD, Department of Biostatistics, University of Texas MD Anderson Cancer Center, 7007 Bertner Ave, Unit 1689, Houston, TX 77030 (jjlee@mdanderson.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.